BRIM-3: improved survival with vemurafenib in melanoma with BRAF V600E mutation
Vemurafenib, the first drug targeting the BRAF V600E mutation, reduced deaths by 63 percent compared with dacarbazine chemotherapy in metastatic melanoma, launching targeted therapy in the disease.
Overview
Phase 3 trial of 675 patients with previously untreated BRAF V600E-mutant metastatic melanoma randomised to vemurafenib or dacarbazine.
At interim analysis, the hazard ratio for death was 0.37 and for progression 0.26, with response of 48 versus 5 percent; cutaneous squamous cell carcinomas, arthralgia and photosensitivity were the characteristic toxicities, and the data monitoring board recommended crossover.
- Hazard ratio for death 0.37; for progression 0.26 at interim analysis.
- Objective response 48 percent vs 5 percent.
BRAF testing became mandatory in advanced melanoma and vemurafenib the first approved BRAF inhibitor; combination with MEK inhibitors soon replaced monotherapy.
- Early analysis; responses were often short because of acquired resistance.
- Keratoacanthomas and squamous cell carcinomas in about 18 percent.
Similar pages
not linked directly; found by shared links- Key paperCOLUMBUS: encorafenib plus binimetinib versus vemurafenib or encorafenib in BRAF-mutant melanoma
Shares Vemurafenib, BRAF V600-mutant melanoma.
- Key paperCOMBI-AD: adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma
Shares BRAF V600-mutant melanoma, New England Journal of Medicine.
- PersonKeith T. Flaherty
Shares Vemurafenib, BRAF V600-mutant melanoma.
- TrialcoBRIM
Shares Vemurafenib, BRAF V600-mutant melanoma.
- TrialCOLUMBUS
Shares Vemurafenib, BRAF V600-mutant melanoma.
- TermBRAF V600E mutation
Shares Vemurafenib, BRAF V600-mutant melanoma.
- PathwayMelanoma (KEGG map)
Shares Vemurafenib, BRAF V600-mutant melanoma.
- TreatmentCobimetinib
Shares Vemurafenib, BRAF V600-mutant melanoma.